ZyVersa Therapeutics, a clinical stage specialty biopharmaceutical company, has announced the publication of an article in Clinical Immunology that demonstrates the association between renal NLRP3 inflammasome activation and lupus nephritis disease activity. Lupus nephritis is characterized by inflammation in the kidney, protein leakage into the urine, and progressive kidney damage. The study found that NLRP3 inflammasomes were extensively activated in the kidneys of patients with lupus nephritis, with higher levels of activation in those with more severe forms of the disease. Inflammasome activation was positively correlated with clinicopathological indices of lupus nephritis.
ZyVersa is currently developing an Inflammasome ASC Inhibitor IC 100, which can inhibit multiple types of inflammasomes including NLRP3 inflammasomes. This inhibitor targets ASC specks associated with damaging inflammation.
The research published in Clinical Immunology provides support for inflammasome inhibition as a promising treatment for lupus nephritis. Unlike other inhibitors that only block initiation of the inflammatory cascade, Zy